Abstract | OBJECTIVE: DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: Only clinical trials evaluating cardiovascular end points of statins used in patients with ESRD were included. DATA SYNTHESIS: In patients with ESRD, CVD is the leading cause of death. Statin therapy has been evaluated in 3 clinical trials in patients with ESRD. The 4D and AURORA trials failed to show a benefit with statin therapy, and the SHARP trial, although positive, also included patients with earlier stages of chronic kidney disease. Despite the lack of efficacy, statin therapy was well tolerated. The cause of cardiovascular death in this patient population may not be a result of atherosclerotic events and possibly dependent on the type of renal replacement therapy. For patients on hemodialysis, lipid profiles may not be amenable to statin therapy. CONCLUSIONS:
Statin therapy has failed to significantly alter the course of CVD events in patients with ESRD. Evidence supports avoiding the routine use of statins in this patient population and instead reserving them for patients with elevated cholesterol levels or those with recent CVD events.
|
Authors | Carrie W Nemerovski, Jona Lekura, Michelle Cefaretti, Pooja T Mehta, Carol L Moore |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 47
Issue 10
Pg. 1321-9
(Oct 2013)
ISSN: 1542-6270 [Electronic] United States |
PMID | 24259696
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Topics |
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Kidney Failure, Chronic
(drug therapy)
- Treatment Outcome
|